<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215991</url>
  </required_header>
  <id_info>
    <org_study_id>1704R2133</org_study_id>
    <secondary_id>2019-002121-30</secondary_id>
    <nct_id>NCT04215991</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Patients</brief_title>
  <official_title>An Open-label Study With a Nonrandomized Single-dose Phase in Subjects With Suspected or Confirmed Aerobic Gram-negative Bacterial Infections Followed by a Randomized, Multiple-dose, Active-controlled Phase in Subjects With Suspected or Confirmed Complicated Urinary Tract Infection (cUTI), Hospital-acquired Pneumonia (HAP) or Ventilator-associated Pneumonia (VAP) to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Subjects 3 Months to &lt; 18 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety, tolerability, and pharmacokinetics (PK) of cefiderocol after&#xD;
      single-dose administration in hospitalized pediatric patients 3 months to &lt; 12 years of age&#xD;
      with suspected or confirmed aerobic Gram-negative bacterial infections and after&#xD;
      multiple-dose administration in hospitalized pediatric patients 3 months to &lt; 18 years of age&#xD;
      with suspected or confirmed complicated urinary tract infection (cUTI), hospital-acquired&#xD;
      pneumonia (HAP), or ventilator-associated pneumonia (VAP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of a nonrandomized single-dose phase in children aged 3 months to less&#xD;
      than 12 years with suspected or confirmed aerobic Gram-negative bacterial infections and a&#xD;
      randomized multiple-dose, active-comparator (SOC) phase in children aged 3 months to less&#xD;
      than 18 years with cUTI, HAP, or VAP to assess the PK, safety, and tolerability of&#xD;
      cefiderocol in hospitalized patients requiring systemic antibiotics for an expected 5 to 14&#xD;
      days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">April 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events in the Single Dose Phase</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Cefiderocol in the Single Dose Phase</measure>
    <time_frame>Day 1, 1 (cohort 2 only), 3, 3.5 (cohort 2 only), 5, and 8 hours after the start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve Extrapolated from Time 0 to Infinity (AUCinf) of Cefiderocol in the Single Dose Phase</measure>
    <time_frame>Day 1, 1 (cohort 2 only), 3, 3.5 (cohort 2 only), 5, and 8 hours after the start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Half-life of Cefiderocol in the Single Dose Phase</measure>
    <time_frame>Day 1, 1 (cohort 2 only), 3, 3.5 (cohort 2 only), 5, and 8 hours after the start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events in the Multiple Dose Phase</measure>
    <time_frame>Up to 28 days after last dose (33 to 42 days depending on treatment duration)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration of Cefiderocol in the Multiple Dose Phase</measure>
    <time_frame>During one of the dosing intervals from Day 5-14, 1 (cohort 2 1 and 2 only), 3, 3.5 (cohorts 1 and 2 only), 5, and 8 hours after the start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve Over the Dosing Interval τ (AUC0-τ) of Cefiderocol in the Multiple Dose Phase</measure>
    <time_frame>During one of the dosing intervals from Day 5-14, 1 (cohort 2 1 and 2 only), 3, 3.5 (cohorts 1 and 2 only), 5, and 8 hours after the start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Half-life of Cefiderocol in the Multiple Dose Phase</measure>
    <time_frame>During one of the dosing intervals from Day 5-14, 1 (cohort 2 1 and 2 only), 3, 3.5 (cohorts 1 and 2 only), 5, and 8 hours after the start of infusion</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Gram-negative Bacterial Infections</condition>
  <condition>Hospital Acquired Pneumonia (HAP)</condition>
  <condition>Complicated Urinary Tract Infection (cUTI)</condition>
  <condition>Ventilator Associated Pneumonia (VAP)</condition>
  <arm_group>
    <arm_group_label>Single Dose Phase: Cefiderocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of cefiderocol administered intravenously on Day 1, in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose Phase: Cefiderocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive cefiderocol administered intravenously every 8 hours for 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg.&#xD;
Dosage may be adjusted based on renal function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose Phase: Standard of Care Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive standard of care treatment according to local standards.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefiderocol</intervention_name>
    <description>Administered intravenously over 3 hours</description>
    <arm_group_label>Multiple Dose Phase: Cefiderocol</arm_group_label>
    <arm_group_label>Single Dose Phase: Cefiderocol</arm_group_label>
    <other_name>Fetroja</other_name>
    <other_name>S-649266</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care administered will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.</description>
    <arm_group_label>Multiple Dose Phase: Cefiderocol</arm_group_label>
    <arm_group_label>Multiple Dose Phase: Standard of Care Alone</arm_group_label>
    <arm_group_label>Single Dose Phase: Cefiderocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject's parent(s) or legally authorized representative(s) (LAR) provides written&#xD;
             informed consent in accordance with regional- and country-specific laws and&#xD;
             regulations&#xD;
&#xD;
          2. Subject provides written informed assent, when feasible (age of assent to be&#xD;
             determined by institutional review board/independent ethics committee [IRBs/IECs] or&#xD;
             be consistent with local legal requirements)&#xD;
&#xD;
          3. Hospitalized subject is 3 months to &lt; 18 years of age at the time written informed&#xD;
             consent/assent is obtained for the multiple-dose phase. Hospitalized subject is 3&#xD;
             months to &lt; 12 years of age at the time written informed consent/assent is obtained&#xD;
             for the single-dose phase.&#xD;
&#xD;
          4. Single-dose phase: Subject has a suspected or confirmed infection type (including but&#xD;
             not limited to cUTI, cIAI (including pneumonia, HAP/VAP), and sepsis or BSI) that&#xD;
             requires hospitalization for treatment with IV antibiotics.&#xD;
&#xD;
             Multiple-dose phase: Subject has a suspected or confirmed cUTI, HAP, or VAP that&#xD;
             requires hospitalization for treatment with IV antibiotics&#xD;
&#xD;
          5. If subject is a sexually active female of childbearing potential and has reached&#xD;
             menarche or Tanner stage 3, subject agrees to use barrier contraception (including&#xD;
             condom, diaphragm, or cervical cap) with spermicide or agrees to use a highly&#xD;
             effective method of contraception (including contraceptive implant, injectable&#xD;
             contraceptive, combination oral contraceptive, or an intrauterine [IUD] contraceptive&#xD;
             device) from Screening up to 28 days after administration of the last dose of&#xD;
             cefiderocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a documented history of any hypersensitivity or allergic reaction to any&#xD;
             β-lactam antibiotic (Note: for β-lactams, a history of a mild rash followed by&#xD;
             uneventful re-exposure is not a contraindication to enrollment)&#xD;
&#xD;
          2. Multiple-dose only: Subject has an infection caused only by a confirmed Gram-positive&#xD;
             pathogen&#xD;
&#xD;
          3. Subject has a suspected or confirmed central nervous system (CNS) infection (eg,&#xD;
             meningitis, brain abscess, shunt infection) or osteomyelitis (which would require&#xD;
             prolonged antibiotic therapy)&#xD;
&#xD;
          4. Subject has cystic fibrosis&#xD;
&#xD;
          5. Single-dose phase: Subject has moderate or severe renal impairment based on estimated&#xD;
             glomerular filtration rate (eGFR) (based on the Schwartz equation if ≥ 3 months to &lt; 1&#xD;
             year of age and modified Bedside Schwartz equation if ≥ 1 to &lt; 18 years of age) of &lt;&#xD;
             60 mL/min/1.73 m² at Screening&#xD;
&#xD;
             Multiple-dose phase: Subject has an eGFR (based on the Schwartz equation if ≥ 3 months&#xD;
             to &lt; 1 year of age and modified Bedside Schwartz equation if ≥ 1 to &lt; 18 years of age)&#xD;
             of &lt; 15 mL/min/1.73 m² at Screening&#xD;
&#xD;
          6. Subject has end-stage renal disease (ESRD), is on hemodialysis (HD), or receiving&#xD;
             continuous venovenous hemofiltration (CVVH)&#xD;
&#xD;
          7. Subject has experienced shock in the prior month or is in shock at the time of&#xD;
             Screening.&#xD;
&#xD;
          8. Subject has severe neutropenia or is severely immunocompromised&#xD;
&#xD;
          9. Subject has multiorgan failure&#xD;
&#xD;
         10. Subjects with a life expectancy of &lt; 30 days due to severity of a concurrent illness&#xD;
&#xD;
         11. Subject is a female who has a positive pregnancy test at Screening&#xD;
&#xD;
         12. Subject is a female who is breastfeeding&#xD;
&#xD;
         13. Subject has received any other investigational medicinal product (IMP) within 30 days&#xD;
&#xD;
         14. Subject has any condition or circumstance that, in the opinion of the investigator,&#xD;
             would compromise the safety of the subject or the quality of the study data, including&#xD;
             acute trauma to the pelvis or urinary tract&#xD;
&#xD;
         15. Subject is receiving vasopressor therapy at Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <phone>800-849-9707</phone>
    <email>Shionogiclintrials-admin@shionogi.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queensland Children's Health Precinct Level 8, Centre for Children's Health Research 62 Graham Street</name>
      <address>
        <city>South Brisbane Queensland</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital &quot;ATTIKON&quot; 3rd Pediatric Clinic of NKUA</name>
      <address>
        <city>Chaidari</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heraklion University General Hospital</name>
      <address>
        <city>Heraklion, Crete</city>
        <zip>7110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hippokration Hospital 3rd Pediatric Clinic of AUTH Konstantinoupoleos 49</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki Papageorgiou</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kauno klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klaipeda Children's Hospital</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92140</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatría &quot;Laboratorio de la Unidad de Apoyo a la Investigación Clínica&quot;, Planta Baja Col. Insurgentes Cuicuilco, Delegacion Coyoacán Av. Insurgentes Sur 3700-C</name>
      <address>
        <city>Ciudad de México</city>
        <zip>4530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Hospital 278, El retiro, Torre Piso 10, Infectología Ped.</name>
      <address>
        <city>Guadalajara Jalisco</city>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Especialidades Ped Via España y Calle Zarak</name>
      <address>
        <city>Ciudad de Panama</city>
        <zip>0801</zip>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosital del Niño, Epidemiologia</name>
      <address>
        <city>Panama City</city>
        <zip>0816-00383</zip>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chong Hua Hospital</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western Visayas and Medical Center</name>
      <address>
        <city>Jaro Iloilo City</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manila Doctors' Hospital</name>
      <address>
        <city>Metro Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Val d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar, Passeig Marítim 25-29</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Noncommercial Enterprise of Kharkiv Regional Council &quot; V.I.Shapoval Regional Clinical Center of Urology and Nephrology&quot;, Department of Children Urology # 7</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vinnytsa Regional Children's Hospital</name>
      <address>
        <city>Vynnytsia</city>
        <zip>21000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zaporizhzhia Regional Children Chinical Hospital</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Greece</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Philippines</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Healthcare-Associated Pneumonia</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

